Akeso, Inc. (09926.HK) Latest Company News

Sep 4, 2026, 05:33 UTC
CStone Pharmaceuticals reported first-half 2026 results with revenue of 1.806 billion yuan, up 27.9% year-on-year, and a net loss attributable to shareholders of 424 million yuan.
Source:
- aastocks.com
Sep 4, 2026, 01:43 UTC
Akeso announced that its self-developed bispecific antibody ivonescimab achieved statistically significant and clinically beneficial positive results in an interim overall survival analysis of the Phase III HARMONi-2 study for first-line treatment of PD-L1-positive non-small cell lung cancer.
Source:
- aastocks.com
- aastocks.com
Sep 2, 2026, 21:41 UTC
Akeso Inc. announced positive overall survival results from the Phase III HARMONi-2 study, showing ivonescimab monotherapy significantly improved OS versus pembrolizumab in PD-L1-positive advanced NSCLC.
Source:
Aug 27, 2026, 14:02 UTC
Akeso Inc. reported its first-half 2026 financial results, with revenue of RMB 1.806 billion, up 27.92% year-on-year, and a net loss of RMB 447 million, narrowing from a loss of RMB 588 million in the same period of 2025.
Source:
Aug 25, 2026, 22:00 UTC
Akeso Inc. announced positive topline results from the Phase III HARMONi-GI1 study of ivonescimab plus chemotherapy in advanced biliary tract cancer, showing statistically significant overall survival benefit versus durvalumab plus chemotherapy.
Source:
Aug 12, 2026, 13:19 UTC
Akeso announced that its drug Evdaze (ivonescimab) combined with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer received marketing approval from China's National Medical Products Administration on August 12.
Source:
Aug 9, 2026, 13:40 UTC
China's National Healthcare Security Administration included two indications of Akeso's ivonescimab in the national medical insurance catalog, with the latest addition via a simplified renewal path without triggering a price cut.
Source:
- wap.eastmoney.com
- yicai.com
Aug 5, 2026, 12:28 UTC
On August 5, 2026, Akeso announced that its overseas partner Summit Therapeutics will initiate a global Phase II/III clinical study (HARMONi-GU1/AK112-3008) combining ivonescimab with enfortumab vedotin for first-line treatment of locally advanced or metastatic urothelial carcinoma, with Akeso leading the China portion and Summit leading overseas portions.
Source:
- finance.sina.cn
Jul 24, 2026, 08:40 UTC
Libo Medicine (09637) announced that its joint representatives have fully exercised the 15% over-allotment option, involving 8.5133 million H-shares at an issue price of HKD 22.6 per share, raising net additional proceeds of HKD 184.7 million to cover over-allotments in the international offering.
Source:
- aastocks.com
Jul 20, 2026, 05:49 UTC
Akeso announced the dosing of the first patient in a Phase II clinical study of its TROP2/Nectin-4 bispecific ADC AK146D1 in combination with ivonescimab for advanced NSCLC.
Source:
- manilatimes.net
- prnewswire.com
Jun 15, 2026, 06:52 UTC
Akeso enrolled the first patient in a Phase Ib/II clinical study of its next-generation HER3 ADC AK138D1, alone or with ivonescimab, for advanced breast cancer.
Source:
- prnewswire.com
Jun 1, 2026, 07:02 UTC
Akeso is investing significantly to expand manufacturing of its lung cancer drug.
Source:
- bloomberg.com
May 31, 2026, 12:00 UTC
Akeso and Summit Therapeutics presented positive Phase 3 trial results for their experimental lung cancer drug ivonescimab at the American Society of Clinical Oncology annual meeting.
Source:

09926.HK

CStone Pharmaceuticals reported first-half 2026 results with revenue of 1.806 billion yuan, up 27.9% year-on-year, and a net loss attributable to shareholders of 424 million yuan.

Akeso announced that its self-developed bispecific antibody ivonescimab achieved statistically significant and clinically beneficial positive results in an interim overall survival analysis of the Phase III HARMONi-2 study for first-line treatment of PD-L1-positive non-small cell lung cancer.

Akeso Inc. announced positive overall survival results from the Phase III HARMONi-2 study, showing ivonescimab monotherapy significantly improved OS versus pembrolizumab in PD-L1-positive advanced NSCLC.

Akeso Inc. reported its first-half 2026 financial results, with revenue of RMB 1.806 billion, up 27.92% year-on-year, and a net loss of RMB 447 million, narrowing from a loss of RMB 588 million in the same period of 2025.

Akeso Inc. announced positive topline results from the Phase III HARMONi-GI1 study of ivonescimab plus chemotherapy in advanced biliary tract cancer, showing statistically significant overall survival benefit versus durvalumab plus chemotherapy.

Akeso announced that its drug Evdaze (ivonescimab) combined with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer received marketing approval from China's National Medical Products Administration on August 12.

China's National Healthcare Security Administration included two indications of Akeso's ivonescimab in the national medical insurance catalog, with the latest addition via a simplified renewal path without triggering a price cut.

Libo Medicine (09637) announced that its joint representatives have fully exercised the 15% over-allotment option, involving 8.5133 million H-shares at an issue price of HKD 22.6 per share, raising net additional proceeds of HKD 184.7 million to cover over-allotments in the international offering.

Akeso announced the dosing of the first patient in a Phase II clinical study of its TROP2/Nectin-4 bispecific ADC AK146D1 in combination with ivonescimab for advanced NSCLC.

Akeso enrolled the first patient in a Phase Ib/II clinical study of its next-generation HER3 ADC AK138D1, alone or with ivonescimab, for advanced breast cancer.

Akeso is investing significantly to expand manufacturing of its lung cancer drug.

Akeso and Summit Therapeutics presented positive Phase 3 trial results for their experimental lung cancer drug ivonescimab at the American Society of Clinical Oncology annual meeting.